

27 **Abstract**

28 Purpose

29 The treatment efficacy of radiation therapy for lung tumors can be increased by
30 compensating for breath-induced tumor motion. In this study we quantitatively examine a
31 mathematical model of pseudo-mechanical linkages between an external surrogate signal
32 and lung tumor motion.

33 Methods

34 A spring-dashpot system based on the Voigt model was developed to model the correlation
35 between abdominal respiratory motion and tumor motion during lung radiotherapy. The
36 model was applied to clinical data obtained from 52 treatments (“beams”) from 10 patients,
37 treated on the Mitsubishi Real-Time Radiation Therapy system, Sapporo, Japan. In Stage 1,
38 model parameters were optimized for individual patients and beams to determine reference
39 values and to investigate how well the model can describe the data. In Stage 2, for each
40 patient the optimal parameters determined for a single beam were applied to data from other
41 beams to investigate whether a beam-specific set of model parameters is sufficient to model
42 tumor motion over a course of treatment.

43 Results

44 In Stage 1 the baseline root mean square (RMS) residual error for all individually-optimized
45 beam data was 0.90 ± 0.40 mm (mean \pm 1 standard deviation). In Stage 2, patient-specific
46 model parameters based on a single beam were found to model the tumor position closely,
47 even for irregular beam data, with a mean increase with respect to Stage 1 values in RMS
48 error of 0.37 mm. On average the obtained model output for the tumor position was 95% of
49 the time within an absolute bound of 2.0 mm and 2.6 mm in Stage 1 and 2, respectively. The
50 model was capable of dealing with baseline, amplitude and frequency variations of the input
51 data, as well as phase shifts between the input abdominal and output tumor signals.

52 Conclusions

53 These results indicate that it may be feasible to collect patient-specific model parameters
54 during or prior to the first treatment, and then retain these for the rest of the treatment period.
55 The model has potential for clinical application during radiotherapy treatment of lung tumors.

56

57 **Keywords:** spring-dashpot model, radiotherapy, lung tumor modeling, respiration,
58 differential equation

59 **1. Introduction**

60 Lung cancer was the most commonly diagnosed cancer worldwide in 2008, with an
61 incidence rate of over 1.5 million new cases, or 12 % of the total new cancer diagnoses¹. It
62 was also the most common cause of death from cancer, accounting for 17% of all cancer
63 deaths. Radiation therapy is a common modality for lung cancer treatment, however
64 treatment efficacy is limited by the motion of the lungs during respiration², which is primarily
65 driven by diaphragm motion, and to a lesser extent by chest motion. The magnitude of lung
66 tumor motion depends on patient-specific breathing and tumor characteristics, and is usually
67 most pronounced along the superior-inferior (SI) axis, compared to the anterior-posterior
68 (AP) and lateral directions³. One study, which included 39 patients treated with the Real-
69 Time Radiation Therapy system in Sapporo, Japan, found a median tumor movement of 1.1
70 mm, 2.3 mm and 5.4 mm in lateral, AP and SI direction, respectively⁴.

71 Typically, for lung tumors the clinical target volume (CTV) is enlarged to the internal target
72 volume (ITV) with the intent of ensuring sufficient tumor coverage in the presence of motion⁵.
73 This strategy can result in excessive irradiation of surrounding healthy tissue, or marginal
74 miss of the tumor⁶. The high doses required for tumor control are close to or above the
75 tolerance level for healthy tissues, resulting in increased side effects, or requiring a reduction
76 in dose to the tumor, decreasing tumor control probability (TCP)^{7, 8}. In this way,
77 compensating for the presence of respiratory motion of lung tumors can improve the
78 therapeutic ratio and thus survival rates⁹.

79 One way to compensate for tumor motion is by means of real-time tumor tracking and
80 motion compensation^{8, 10-14}. Motion tracking is complicated by variations in baseline (the
81 position about which the quasi-periodic motion occurs), frequency, oscillatory amplitude and
82 oscillatory form, despite the overall superficial regularity of respiratory motion. These effects
83 can differ widely between patients but can also vary over the course of treatment of a single
84 patient⁷. Methods to suppress such variability include abdominal compression to reduce

85 tumor mobility, breath control techniques (active or passive) and respiratory gating of
86 irradiation^{3, 7, 15-19}, with the latter usually based on external surrogate motion. All of these
87 techniques have some limitations, such as the need for active patient cooperation,
88 consistent ability to maintain total lung capacity²⁰, or a lengthened treatment time for gated
89 therapy due to the required beam-off periods.

90 Modeling of the respiratory-induced lung tumor motion can facilitate dynamic tracking and
91 compensation for real-time and gated treatments^{4, 7, 8, 19}. Direct tumor tracking systems may
92 either use portal imaging with implanted fiducial markers in the tumor^{20, 23, 24} or without any
93 markers^{10, 13, 21, 22}. The former is used in conjunction with a diagnostic x-ray imaging system,
94 however, continuous imaging can impart a considerable radiation dose which is not always
95 clinically justifiable²⁵. For markerless tracking approaches the tumor is tracked directly in the
96 portal EPID images.

97 By contrast, indirect tumor tracking systems use internal or external surrogates to obtain
98 tracking signals. A model is then required to relate the surrogate to tumor motion. Examples
99 of external respiratory surrogates are a spirometer, strain gauge or abdominal markers²⁰,
100 while an internal surrogate can be the diaphragm motion²⁶. Such indirect approaches require
101 the relationship between surrogate and internal tumor motion to be consistent and well
102 correlated²⁷. The benefits of indirect tracking include the elimination of risks associated with
103 fiducial implantation, extra radiation doses, and direct tracking failures. Most models
104 correlating surrogate data to tumor motion have been so-called 'black box' or 'grey box'
105 approaches, for which the internal behavior of the physical system is not or only partially
106 known, respectively. These models consider the input and output data, but not the exact
107 physical relationship between them. Various approaches of this form include linear
108 correspondence models^{9, 28}, composites of baseline drift, frequency variation, fundamental
109 pattern change and random observation noise⁷, characterization of the motion with a
110 piecewise linear model of defined stages of the breathing cycle²⁹, state-based probabilistic
111 models³⁰, least-squares parameter estimation and systems identification³ or adaptive neural

112 networks³¹. These models generally require a large amount of sample data which
113 encompasses the range of possible relationships between the input and output states. Many
114 of the previous external surrogate models tend to deal poorly with irregularities in the
115 breathing pattern, such as baseline drift or a hysteresis³¹, a lag or phase shift between
116 internal and external motions^{27, 32, 33}, and usually have a strong dependence on tumor and
117 marker locations, motion dimensions and type of breathing pattern^{3, 4, 28}. One of the more
118 promising models is the model by Cervino *et al.*²⁶ using an internal surrogate signal of the
119 diaphragm; however the practical benefits of using an external signal warrant further
120 investigation into external abdominal surrogates.

121 A more physical approach to the problem models lung motion as a contact problem of
122 elasticity theory by describing the physiology of breathing using elastic constants to directly
123 model the lung tissue³⁴. A different approach was explored by Wilson and Meyer^{35, 36} who
124 presented a comprehensive physical 3D system of springs and dashpots to model the
125 correlation of an external abdominal respiratory signal and the lung tumor motion, rather
126 than directly modeling the actual lung tissue²⁴. Wilson and Meyer showed mathematically
127 that it is possible to formally simplify the three-dimensional model to a one-dimensional
128 model when SI motion of the tumor dominates.

129 To overcome some of the physical intrinsic limitations for the practical application of the
130 above approach, the first aim of this paper was to refine the Wilson and Meyer model in the
131 one-dimensional realm. The relationship between lung tumor and external abdominal marker
132 movement is considered for the primary dimension of motion, namely the SI direction for the
133 tumor and the AP direction for the abdominal signal. The second objective was to apply the
134 refined model to a large and realistic clinical data set of tumor motion from a cohort of lung
135 cancer patients treated with the Mitsubishi Real-Time Radiation Therapy system in Sapporo,
136 Japan to investigate the model behavior on an intra- and inter-patient specific basis.


137

138 **2. Material and Methods**

139 *2.1 Mathematical model*

140 Following the methodology of Wilson & Meyer³⁵, we model the correlation between the
141 surrogate data provided by abdominal motion and the target data of the lung tumor motion
142 with a pseudo-mechanical system. This system is composed of springs and dashpots, the
143 latter providing a damping effect. In general, a spring-dashpot unit can be composed of
144 springs and dashpots in series, parallel, or some combination thereof. Three of the most
145 frequently-used configurations in other applications are shown in Figure 1. The full three-
146 dimensional system of Wilson & Meyer (2009) featured a Voigt unit able to act in each
147 Cartesian direction of motion.¹

148



149

150 **Figure 1:** (a) Maxwell model (b) Voigt model (c) Standard Linear Solid model. *S*
151 denotes a spring and *d* denotes a dashpot.

152

¹ Note that these were incorrectly drawn in the Wilson & Meyer paper as Maxwell units.

153 Asymptotic analysis³⁵ shows that when the SI motion of the tumor is dominant the motion is
154 well-modeled by a single Voigt unit acting in the SI direction, with the tumor attached at one
155 end and the abdominal system providing input at the other. It is this pseudo-one dimensional
156 class of tumor motion which we consider in this paper.

157 The variable x is the tumor displacement (in mm) from a resting equilibrium position in the
158 SI direction. The Hookean spring has associated parameter k , which we normalize on the
159 unknown tumor mass m , to give the characteristic spring parameter ω , measured in units of
160 s^{-1} . Similarly, the dashpot, characterized by the parameter λ (in units of s^{-1}) provides a
161 retarding force directly proportional to the tumor velocity. Although the dominant time-
162 dependent abdominal motion, $f(t)$, measured in mm, is in the AP direction perpendicular to
163 the dominant tumor motion direction, this component of the abdominal signal is linearly
164 scaled and used as input to the model. This forcing input signal, $x^*(t)$, is therefore related to
165 the measured data by $x^* = \delta f$, with the scale factor δ , having units s^{-2} , being determined
166 under optimization. This approach reduces the dimension of the parameter space of Wilson
167 & Meyer by one, and also allows a wider range of parameter values to be studied, both of
168 which enable the model to be more readily optimized.

169 Following Wilson & Meyer³⁵ but with the above notation, the tumor motion is given by

170
$$\frac{d^2 x}{dt^2} = -2\lambda \frac{dx}{dt} - \omega^2 x + \delta f \quad (1)$$

171 The forcing term of the original Wilson & Meyer³⁵ model was modeled on the mechanics of a
172 rigid rod whose undetermined length was to be optimized, and which connected the
173 diaphragm to the location of the external markers. The forcing has been simplified here by
174 the term δf just described. Otherwise, equation (1) above corresponds to the principal
175 equation studied in Wilson & Meyer³⁵, namely equation (17) of that paper.

176 The model will be shown to hold for all lung cancer patients from the cohort of patients with
177 reliable data considered in this work, with values of the parameter triplet $(\omega, \lambda, \delta)$ derived
178 from a “training” subset of patient data (detailed below), and successfully applied to model
179 the remaining data.

180 *2.2 Numerical approach*

181 Equation (1) was rewritten as two coupled first-order ordinary differential equations, which
182 were solved for each set of training data using the MATLAB™ differential equation solver
183 *ode45*, which is recommended for non-stiff problems³⁷. The resulting output data were
184 optimized with respect to the model parameter triplet $(\omega, \lambda, \delta)$ using the MATLAB
185 *fminsearch* routine in combination with a cost function: an iterative process used to find the
186 minimum of the root mean squared error (RMS) (2) between the measured (1D) tumor
187 position data, \mathbf{X} , and the (1D) model output values, \mathbf{x} (at each step, i , of n time steps).

$$188 \quad RMS = \left(\frac{\sum_{i=1}^n (X_i - x_i)^2}{n} \right)^{\frac{1}{2}} \quad (2)$$

189 The algorithm starts with an initial estimate of the triplet based on the model characterization
190 in Wilson & Meyer and proceeds via a process of unconstrained non-linear optimization with
191 a Simplex search method. Optimization is initially patient- and beam-specific and is based on
192 a set of “training” data constituting approximately 2 minutes of patient data. The algorithm
193 terminates when the RMS error is less than 10^{-3} or when a maximum number of 100
194 iterations have been reached.

195 In *Stage 1* of our work, optimized parameters obtained in this way are used to model the
196 tumor motion via numerical solutions to equation (1) for each beam to obtain reference
197 values. We refer to this stage as ‘optimized’.

198 In *Stage 2* ('non-optimized') we take the optimized parameters from a single beam – e.g.
199 Day 1, Beam 1– and use these to model the tumor motion via (1) for that patient's
200 respiratory data obtained from other beams on the same day and consecutive days. The
201 comparison between the predicted tumor position, \mathbf{x} , and the clinical data, \mathbf{X} , is presented
202 and discussed in sections 3 and 4. The distribution of differences between predicted and
203 measured tumor positions is tested using the statistical method of Jarque-Bera, which is a
204 measure of the goodness-of-fit of a time series of data to a normal curve, based on a
205 consideration of the skewness and kurtosis of the data.³⁸

206 *2.3 Clinical data*

207 The clinical data consist of 3D internal fiducial-based motion obtained using radiopaque
208 fiducial markers implanted and visualized in real-time using stereoscopic diagnostic x-ray
209 fluoroscopy, collected using a Mitsubishi Real-Time Radiation Therapy system, at the
210 Nippon Telegraph and Telephone Corporation Hospital, Sapporo, Japan²⁷. This was
211 obtained simultaneously with 1D external abdominal motion, collected on an independent
212 co-ordinate system using a laser based AZ-733V "RespGate" made by Anzai Medical,
213 Tokyo, Japan. The data set consisted of motion results from eleven patients (patient 1-11)
214 with lung cancer at various sites, with a total of 171 treatment beams for up to ten
215 consecutive treatment fractions (day 1-10) and four beam configurations per fraction (beam
216 1-4)². The data for patient 11 were unreliable and not included. The patients were not a
217 random sample of the general lung cancer population, but were selected on the basis of an
218 estimated internal marker motion of more than 10 mm peak to peak (SI, lateral or AP
219 direction). The data show phase shifts of the internal-external data (one signal lagging the
220 other) in the SI direction that are mostly between 100 and 200 ms.

221 The data were not acquired in a common coordinate system with absolute spatial co-
222 ordinates and therefore they could not be normalized to a common reference point. Spatial

² Patient 5 had eight fractions, then a further four two months later. The analysis was kept consistent.

223 baselines for the tumor and abdominal markers were defined by normalizing on the mean of
224 each beam data.

225 For baseline values in Stage 1 the model was initially applied to data from 52 treatment
226 beams from 10 patients: beam 1 data for all days for all patients (as this type of data was
227 available for all patients), as well as all beams for patients 1-3³. More detailed analysis was
228 then carried out on representative individual patients: one whose model performance was
229 close to the mean of all patients (Patient 7); one with relatively poor model performance
230 (Patient 8); and one with excellent model performance (Patient 10).

231 In the second stage, for each patient the optimal parameters determined for an arbitrarily
232 chosen single beam were applied to data from other beams and treatment days to
233 investigate whether a beam-specific set of model parameters is adequate to model tumor
234 motion over a course of treatment.

235 We also investigate the ability of the model to adapt to irregularities in the clinical data such
236 as unclear tracking data, missing data points, baseline drift and amplitude and frequency
237 variation.

238 **3. Results**

239 *3.1 Stage 1*


240 Applying the optimization algorithm to the data from the 52 clinical treatment beams with the
241 initial estimate parameter triplet $(\omega, \lambda, \delta) = (10 \text{ s}^{-1}, 5 \text{ s}^{-1}, 200 \text{ s}^{-2})$ gave, on average, a root
242 mean square error of 0.90 mm (2 s.f.) and a standard deviation of 0.40 mm between the
243 modeled position and the tumor motion in the superior-inferior direction. The best result from
244 all the beam data modeled, Patient 4, Day 1, Beam 1, had an RMS error of 0.38 mm. An
245 overview of the RMS errors for all patients is shown in Figure 2.

³ Patient 1 (P1) supplied 4 beams from 1 day; P2 and P3 2 beams from 1 day. For the remaining patients we used the Beam 1 data from: 10 days for P4; 12 days for P5; 7 days for P6; 4 days for P7, P8, and P10; and 3 days for P9. The mean duration of the 52 beams was 122.68 ± 65.64 s.

246 The number of iterations required for optimization varied considerably with each beam but
247 was generally less than 100 iterations. A representative example (patient 7) of beam data
248 and the model results with a RMS of 0.69 mm is shown in Figure 3, with optimized
249 parameters $\omega = 10.12 \text{ s}^{-1}$, $\lambda = 5.27 \text{ s}^{-1}$, $\delta = 197.91 \text{ s}^{-2}$.

250 The linear relationship between the position predicted by the model and the actual tumor
251 location was investigated, and the regression correlation coefficient was calculated for each
252 beam studied. The mean correlation from all 52 beams was 0.96 with standard deviation of
253 0.03, which would indicate the existence of strong linear relationships. A graphical analysis
254 of one beam each for the three representative patients is shown in the top row of Figure 4.


255



256

257 **Figure 2:** Average root mean square error (mm) between model output and clinical data for
258 each patient. Representative patients 7, 8 and 10 used for further analysis are marked as

259 'mean', poor' and 'excellent', respectively. Note that the number of beams included to
260 calculate the RMS errors varies between patients.



261


262 **Figure 3:** The clinical data and model output, showing breathing pattern, tumor motion, and
263 model output for Patient 7, Day 4, Beam 1. The lower figure shows a close-up view of part of
264 the tumor data and model output.

265

266 Additionally, we considered the residuals (the differences between predicted and measured
267 tumor positions at all time steps) for each beam, whose elements appeared visually to have
268 a normal-like distribution, although a more rigorous testing of these vectors revealed that
269 only four beams were sufficiently normal to satisfy the Jarque-Bera³⁸ test. The bottom row of
270 Figure 4 shows the histograms of three beams. Note that the best fitting normal probability

271 distribution is scaled to the area of the histograms. The full width at half maximum was 1.6
 272 mm, 3.9 mm and 1.2 mm for patients 7, 8 and 10, (mean, poor, excellent), respectively.

273



274

275 **Figure 4:** Regression plots and residual histograms for three beams: “mean” Patient 7, Day
 276 4, Beam 1 (left); “poor” Patient 8, Day 1, Beam 1 (center); “excellent” Patient 10, Day 1,
 277 Beam 1 (right).

278

279 For clinical applications, a major concern is the duty cycle, i.e. proportion of time, which we
 280 term the *residency*, for which the model output is within a small distance of the actual tumor
 281 position, i.e. within the treatment margin. The residency of the 52 beams was calculated for
 282 bounds on the absolute difference in positions of 1, 2, 3, 4, 5 mm. The residencies from
 283 Patients 7, 8 and 10, and all 52 beams are shown in Table 1. As can be seen from the table,

284 to be resident 95% of the time a bound of 2 mm is required on average. This is commonly
285 also referred to as the 95-percentile error.

286 In the second stage the parameter results obtained from optimizing the Day 1, Beam 1 data
287 for each patient were applied to other beams and days for that patient in lieu of optimizing
288 the data from each beam independently (Stage 1). There was a mean increase in RMS error
289 of 0.37 mm. Results are shown in Table 2.

290 When the robustness of the model was examined with respect to the linear relationship
291 between the tumor position and model prediction, the mean correlation coefficient of the 52
292 beams was 0.96, the same value as when each beam was optimized independently.

293 There was a drop in residency in this second stage as can be seen from Table 3. This time a
294 band width of 2.6 mm was required on average, an increase of 0.60 mm, for 95% residency.

295

296 **Table 1:** Residency analysis for Patient 7, Patient 8, Patient 10 and all 52 beams studied
297 (Stage 1).

Band Width	1 mm	2 mm	3 mm	4 mm	5 mm
Patient 7	72%	97%	99%	100%	100%
Patient 8	50%	84%	96%	99%	99%
Patient 10	92%	99%	100%	100%	100%
All 52 beams	76%	95%	99%	100%	100%

298

299 **Table 2:** Comparison of RMS error results for Patient 7, Patient 8, Patient 10 and all 52
 300 beams studied. The average value given is the mean \pm one standard deviation.

	Average RMS error		
	Stage 1: optimized	Stage 2: non-optimized	Difference
Patient 7	0.91 \pm 0.28 mm	1.16 \pm 0.17 mm	0.25 mm
Patient 8	1.50 \pm 0.28 mm	1.70 \pm 0.10 mm	0.20 mm
Patient 10	0.58 \pm 0.11 mm	0.70 \pm 0.24 mm	0.12 mm
All 52 beams	0.90 \pm 0.40 mm	1.27 \pm 0.51 mm	0.37 mm

301

302 **Table 3:** Residency analysis for Patient 7, Patient 8, Patient 10 and all 52 beams without
 303 further optimization (i.e. Stage 2), using Day 1, Beam 1 parameters.

304

Band Width	1 mm	2 mm	3 mm	4 mm	5 mm
Patient 7	62%	91%	99%	100%	100%
Patient 8	42%	77%	94%	99%	99%
Patient 10	85%	99%	100%	100%	100%
All 52 beams	56%	88%	98%	99%	100%

305

306 3.1.1 Detailed analysis of Patients 7, 8, and 10

307 The means in Table 2 for patients 7, 8, and 10 were obtained from a subset of data available
 308 for those patients. Now we consider all available and reliable data for patients 7, 8, and 10 to
 309 determine whether our initial use of a subset of data biased the results shown in Table 2. In

310 Table 4 we show that no such bias exists, because when all available and reliable⁴ beam
 311 data for Patient 7, Patient 8 and Patient 10 were analyzed, the RMS error and residency
 312 results for Patients 7 and 8 calculated from optimized results from all available beam data
 313 are close to the values shown in Table 2. The changes in the mean correlation coefficients
 314 for Patients 7 and 8 were negligible (about 0.96 in all cases) whereas the mean correlation
 315 coefficient for Patient 10 dropped from 0.99 to 0.98 when all available beam data were
 316 analyzed, in both Stage 1 and Stage 2.

317

318 **Table 4:** Comparison results for all available and reliable data for Patient 7, Patient 8,
 319 Patient 10, and all 52 beams studied. The average value given is the mean \pm one standard
 320 deviation.

	Average RMS error		Band width for 95% residency	
	Stage 1 optimized	Stage 2 non-optimized	Stage 1 optimized	Stage 2 non-optimized
Patient 7	0.95 \pm 0.40 mm	1.36 \pm 0.38 mm	2.1 mm	2.9 mm
Patient 8	1.61 \pm 0.34 mm	1.87 \pm 0.31 mm	3.0 mm	3.5 mm
Patient 10	0.84 \pm 0.28 mm	0.95 \pm 0.35 mm	1.7 mm	2.0 mm
All 52 beams	0.90 \pm 0.40 mm	1.27 \pm 0.51 mm	2.0 mm	2.6 mm

321

⁴One beam was omitted for patient 10 because it contained a substantial amount of missing data, and obviously spurious measurements.

322 *3.1.2 Sensitivity of optimization for different days.*

323 To test the sensitivity to beam and day parameter optimization, non-optimized results were
324 obtained for Patients 7, 8, and 10 using the parameters obtained from optimizing the Day 3,
325 Beam 2 data, a choice made arbitrarily. The change in the average RMS error and the band
326 width required for 95% residency was small as can be seen from Table 5 below, and there
327 was no change in the mean correlation results. This would indicate that different parameter
328 sets obtained from different beams for the same patient give adequate results.

329


330 **Table 5:** Results for all available and reliable data for Patient 7, Patient 8, and Patient 10
331 optimized using Day 3, Beam 2 parameters. The average value given is the mean \pm one
332 standard deviation.

	Average RMS error	Mean correlation coefficient	Band width for 95% residency
Patient 7	1.17 \pm 0.37 mm	0.96	2.5 mm
Patient 8	1.91 \pm 0.28 mm	0.96	3.6 mm
Patient 10	0.95 \pm 0.35 mm	0.98	2.0 mm

333

334 *3.4 Irregular beam data*

335 The model was capable of dealing with data containing irregularities such as missing data
336 covering several seconds (poor tracking of the abdominal motion), spikes in the amplitude of
337 tumor motion and baseline drift. Figure 5 shows an example of the model applied to data
338 containing some initial baseline drift of the breathing signal, a period of missing data, and an
339 unusual rapid variation in amplitude, or "spike". These data problems are important
340 considerations for modeling lung tumor motion to ensure that errors are not avoidably high.




342

343 **Figure 5:** Breathing data (top) and tumor data and model output (middle) for Patient 8, Day
 344 2, Beam 1. Labeled are a lengthy period of missing data and a "spike" in the data. The solid
 345 line for the model data is an interpolation between points and therefore does not represent
 346 actual model output; specifically, the model makes no predictions during periods of missing
 347 breathing data. An initial baseline drift is also apparent. The lower figure shows in greater
 348 resolution how the model copes with the data spike.

349

350 This incomplete data gives a useful clarification of the functioning of the model. The model
 351 was not designed to predict tumor motion in the absence of breathing data, only in the
 352 absence of tumor data. Thus we see that when the breathing data are missing the model
 353 makes no prediction for tumor location. This can be clearly seen in the long period of missing
 354 data around 30s, and also in the much shorter periods around 19s and 62s. In all cases, we
 355 have plotted an interpolated solid line for the model data for consistency with other plots,
 356 although in actual fact the model makes no prediction at those times of missing breathing
 357 data.

358 The RMS error for this beam data is 1.09 mm and the correlation coefficient is 0.98. The
359 band width for 95% residency is 2.1 mm. These results indicate that the model deals well
360 with irregularities in the data. Figure 6 below shows the histogram of residuals and the
361 regression plot for the data presented in Figure 5. The tail of negative residuals in this
362 histogram is long relative to those shown in Figure 4. This is not due to poor systematic
363 performance but rather due to the performance in the short dashpot-mediated recovery
364 period immediately following the spike in Figure 5, lasting less than one second.



365
366
367 **Figure 6:** Residual plot (left) and regression plot (right) for Patient 8, Day 2, Beam 1. The
368 mean is -0.030 and standard deviation 1.09, while the correlation coefficient is 0.98.

369

370 4. Discussion

371 A modified version of the Wilson & Meyer spring-dashpot model has been developed to
372 correlate abdominal motion with lung tumor motion. In its current implementation the
373 approach is capable of modeling the main component of tumor motion in the SI direction.
374 The model was applied to clinical tumor tracking data from 10 patients treated on the
375 Mitsubishi Real-Time Radiation Therapy system in Sapporo, Japan. In the first stage, the
376 model parameters were optimized for each individual beam in order to determine the
377 goodness of fit for each data set. These values served as a benchmark for further evaluation
378 in Stage 2. In Stage 2, the optimized model parameters for one particular beam were used to

379 estimate the output, i.e. tumor motion, for other beams and treatment days in order to
380 evaluate the trade-offs with regard to optimizing each individual beam separately. The
381 motivation for this was to find out whether it is possible for model parameters to be
382 determined on the first day of treatment or even prior to treatment. The mean error
383 determined for Stage 1 was 0.90 ± 0.40 mm, which increased by 0.37 mm in Stage 2. The
384 results were very similar if parameters were used that were initially estimated for other
385 beams for the same patient. This indicates that despite the temporal changes in the
386 abdominal/tumor motion relationship over a treatment course the physical characteristics
387 remain fairly constant, which is reflected in only a small increase in the residual error. This is
388 the advantage of a semi-physical model, such as the one presented here, which aims to
389 model the tissue elasticity as opposed other models which might provide an excellent fit to
390 the input/output data but have no intrinsic relationship to the actual mechanical tissue
391 properties.

392 To put the results into a more clinically relevant context, hypothetical bounds were calculated
393 so that the modeled point location of the tumor would be within the actual point location of
394 the tumor for 95% of the treatment time. This hypothetical bound would account for the
395 inaccuracies of the modeling and assumes otherwise perfect compensation of the tumor
396 motion, by tumor tracking or respiratory gating, for example. The bound calculated for stage
397 1 averaged over 52 beams was 2.0 mm and for Stage 2 it was 2.6 mm. To obtain a better
398 understanding of the variability within the patients, three representative patients were further
399 analyzed, patients 7, 8 and 10, corresponding to a residual error of 0.95 mm ('mean'), 1.61
400 mm ('poor') and 0.84 mm ('excellent') in Stage 1. The residual errors showed a largely
401 Gaussian distribution with minimal offset from the mean indicating that the model did not
402 result in systematic model output errors. The calculated error bounds based on the 95%
403 inclusion criteria calculated for the selected patients were 2.1, 3.0, 1.7 mm, respectively,
404 which gives an indication of the correlation between the residual modeling errors and the

405 resulting position uncertainty, which ultimately feeds into the calculation of appropriate
406 margins.

407 One of the useful features of the spring-dashpot system is that it managed to successfully
408 model baseline drifts and irregular tumor motion. It was also capable of quickly restoring
409 accurate model output when data were missing as shown in Figure 5. The determination of
410 optimal modeling parameters did not include a systematic search of the global parameter
411 space; a downhill search algorithm was used for efficiency. It remains to be investigated if a
412 stochastic search technique, e.g. simulated annealing or approximate Bayesian
413 computation, is required to remove dependence on the initial parameter estimates, but this
414 will be at the expense of higher computational costs. For consistency the initial starting
415 condition for the search was kept constant but it was found that the nominal values of the
416 optimized parameters diverged if different starting conditions were used (data not shown).
417 However, it was found that the resulting residuals were almost identical, which indicates that
418 the solution space is relatively flat. Therefore it was not considered critical but remains an
419 area of further investigation.

420 Indeed, the flatness of the solution space occasionally led to slow convergence of the
421 results. A maximum number of iterations of 100 was imposed on the algorithm as a
422 compromise between full convergence and computational cost; increasing the maximum
423 number of iterations to 200 only marginally reduced the RMS error at the expense of
424 considerably longer computation times. Whether the computation converged or 100
425 iterations were performed had no consistent effect on the parameter variability in Stage 1,
426 defined in terms of the standard deviation of the parameter values as a percentage of the
427 means. However, mean parameter values tended to be one order of magnitude higher in the
428 non-converged cases. Once again, however, the fit parameter variability was not correlated
429 with the goodness of fit in the actual data, further supporting the idea of a relatively flat
430 solution space. The full characterization of this solution space is an open problem.

431 For clinical implementation, several extensions to the current modeling process are needed.
432 One is the extension to a full three dimensional system which also considers the minor axes
433 of tumor motion (AP and lateral) for the sake of completeness for the proportion of patients
434 where this motion is non-negligible. Also, ideally the system should be predictive, as there is
435 a finite time required for the treatment machinery (couch⁸ or multi-leaf collimator¹²) to adjust
436 to the determined change in position. In this context, we also note that phase lag is a well-
437 known effect in spring-dashpot models, but we have not investigated any correlation
438 between the lag and the parameters of the current model. Ultimately, any algorithm has
439 limitations and is dependent on the quality of the input data and therefore the output of the
440 model should be tested and verified with independent means in a clinical setting.

441 **5. Conclusion**

442 A semi-physical spring-dashpot model to correlate breathing to tumor motion in the superior-
443 inferior direction has been presented and applied to clinical tracking data. Optimized model
444 parameters were found to be robust and transferrable to different beams on the same day
445 and consecutive days. Day-to-day variations in the agreement between the model output
446 and the measured data were small, indicating that the model parameters may be determined
447 prior to or on the first day of treatment and then used throughout the course of treatment.
448 The semi-physical nature of the model enabled it to deal with irregularities in the data such
449 as baseline drifts, phase shifts and amplitude and frequency variations. Further work will
450 address the expansion of the model to include all three dimensions and experimental testing
451 and verification of the model output in a clinical setting.

452 **Acknowledgements**

453 We would like to thank Dr. Seiko Nishioka and Dr. Hiroki Shirato, for the clinical data
454 provided from the Nippon Telegraph and Telephone Corporation Hospital in Sapporo, Japan.
455 Thanks also to the Canterbury Medical Research Foundation for financial support for Alicia
456 Cavan.

458 **References**

- 459 1. D. M. Parkin, F. Bray, J. Ferlay and P. Pisani, "Global cancer statistics, 2002," *CA: a*
460 *cancer journal for clinicians* **55**, 74-108 (2005).
- 461 2. T. Bortfeld, S. B. Jiang and E. Rietzel, "Effects of motion on the total dose
462 distribution," *Semin Radiat Oncol* **14**, 41-51 (2004).
- 463 3. J. Meyer, K. Baier, J. Wilbert, M. Guckenberger, A. Richter and M. Flentje, "Three-
464 dimensional spatial modelling of the correlation between abdominal motion and lung
465 tumour motion with breathing," *Acta Oncologica* **45**, 923-934 (2006).
- 466 4. R. Onimaru, H. Shirato, M. Fujino, K. Suzuki, K. Yamazaki, M. Nishimura, H. Dosaka-
467 Akita and K. Miyasaka, "The effect of tumor location and respiratory function on
468 tumor movement estimated by real-time tracking radiotherapy (RTRT) system," *Int J*
469 *Radiat Oncol Biol Phys* **63**, 164-169 (2005).
- 470 5. International Commission on Radiation Units and Measurements. ICRU Report 62.
471 Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU
472 Report 50). Bethesda, MD: ICRU; 1999
- 473 6. A. M. Allen, K. M. Siracuse, J. A. Hayman and J. M. Balter, "Evaluation of the
474 influence of breathing on the movement and modeling of lung tumors," *Int J Radiat*
475 *Oncol Biol Phys* **58**, 1251-1257 (2004).
- 476 7. D. Ruan, J. A. Fessler, J. M. Balter and P. J. Keall, "Real-time profiling of respiratory
477 motion: baseline drift, frequency variation and fundamental pattern change," *Phys*
478 *Med Biol* **54**, 4777-4792 (2009).
- 479 8. J. Wilbert, J. Meyer, K. Baier, M. Guckenberger, C. Herrmann, R. Heß, C. Janka, L.
480 Ma, T. Mersebach, A. Richter, M. Roth, K. Schilling and M. Flentje, "Tumor tracking
481 and motion compensation with an Adaptive Tumor Tracking System (ATTS): System
482 description and prototype testing," *Medical Physics* **35**, 3911-3921 (2008).
- 483 9. E. Nioutsikou, Y. Seppenwoolde, J. R. Symonds-Tayler, B. Heijmen, P. Evans and S.
484 Webb, "Dosimetric investigation of lung tumor motion compensation with a robotic

- 485 respiratory tracking system: an experimental study," *Med Phys* **35**, 1232-1240
486 (2008).
- 487 10. J. Meyer, A. Richter, K. Baier, J. Wilbert, M. Guckenberger and M. Flentje, "Tracking
488 moving objects with megavoltage portal imaging: A feasibility study," *Medical Physics*
489 **33**, 1275-1280 (2006).
- 490 11. M. J. Murphy, "Tracking moving organs in real time," *Semin Radiat Oncol* **14**, 91-100
491 (2004).
- 492 12. P. J. Keall, H. Cattell, D. Pokhrel, S. Dieterich, K. H. Wong, M. J. Murphy, S. S.
493 Vedam, K. Wijesooriya and R. Mohan, "Geometric accuracy of a real-time target
494 tracking system with dynamic multileaf collimator tracking system," *Int J Radiat Oncol*
495 *Biol Phys* **65**, 1579-1584 (2006).
- 496 13. J. Rottmann, M. Aristophanous, A. Chen, L. Court and R. Berbeco, "A multi-region
497 algorithm for markerless beam's-eye view lung tumor tracking," *Phys Med Biol* **55**,
498 5585-5598 (2010).
- 499 14. R. I. Berbeco, F. Hacker, D. Ionascu and H. J. Mamon, "Clinical feasibility of using an
500 EPID in CINE mode for image-guided verification of stereotactic body radiotherapy,"
501 *Int J Radiat Oncol Biol Phys* **69**, 258-266 (2007).
- 502 15. D. Ruan, J. A. Fessler, J. M. Balter, R. I. Berbeco, S. Nishioka and H. Shirato,
503 "Inference of hysteretic respiratory tumor motion from external surrogates: a state
504 augmentation approach," *Phys Med Biol* **53**, 2923-2936 (2008).
- 505 16. M. Partridge, A. Tree, J. Brock, H. McNair, E. Fernandez, N. Panakis and M. Brada,
506 "Improvement in tumour control probability with active breathing control and dose
507 escalation: a modelling study," *Radiother Oncol* **91**, 325-329 (2009).
- 508 17. K. E. Rosenzweig, J. Hanley, D. Mah, G. Mageras, M. Hunt, S. Toner, C. Burman, C.
509 C. Ling, B. Mychalczak, Z. Fuks and S. A. Leibel, "The deep inspiration breath-hold
510 technique in the treatment of inoperable non-small-cell lung cancer," *Int J Radiat*
511 *Oncol Biol Phys* **48**, 81-87 (2000).

- 512 18. S. Shimizu, H. Shirato, S. Ogura, H. Akita-Dosaka, K. Kitamura, T. Nishioka, K.
513 Kagei, M. Nishimura and K. Miyasaka, "Detection of lung tumor movement in real-
514 time tumor-tracking radiotherapy," *Int J Radiat Oncol* **51**, 304-310 (2001).
- 515 19. I. Land, J. A. Mills, K. Young, O. Haas and A. Wilson, "Modelling the effects of lung
516 tumour motion on planning and dose delivery with gated radiotherapy," *Clin Oncol (R
517 Coll Radiol)* **19**, S36 (2007).
- 518 20. H. Yan, F. F. Yin, G. P. Zhu, M. Ajlouni and J. H. Kim, "The correlation evaluation of
519 a tumor tracking system using multiple external markers," *Med Phys* **33**, 4073-4084
520 (2006).
- 521 21. K. Baier and J. Meyer, "Fast image acquisition and processing on a TV camera-
522 based portal imaging system," *Z. Med. Phys.* **15**, 1-4 (2005).
- 523 22. R. I. Berbeco, H. Mostafavi, G. C. Sharp and S. B. Jiang, "Towards fluoroscopic
524 respiratory gating for lung tumours without radiopaque markers," *Phys Med Biol* **50**,
525 4481-4490 (2005).
- 526 23. R. I. Berbeco, S. B. Jiang, G. C. Sharp, G. T. Chen, H. Mostafavi and H. Shirato,
527 "Integrated radiotherapy imaging system (IRIS): design considerations of tumour
528 tracking with linac gantry-mounted diagnostic x-ray systems with flat-panel
529 detectors," *Phys Med Biol* **49**, 243-255 (2004).
- 530 24. H. Shirato, S. Shimizu, T. Kunieda, K. Kitamura, M. van Herk, K. Kagei, T. Nishioka,
531 S. Hashimoto, K. Fujita, H. Aoyama, K. Tsuchiya, K. Kudo and K. Miyasaka,
532 "Physical aspects of a real-time tumor-tracking system for gated radiotherapy," *Int J
533 Radiat Oncol Biol Phys* **48**, 1187-1195 (2000).
- 534 25. Q. Ren, S. Nishioka, H. Shirato and R. I. Berbeco, "Adaptive prediction of respiratory
535 motion for motion compensation radiotherapy," *Phys Med Biol* **52**, 6651-6661 (2007).
- 536 26. L. I. Cervino, A. K. Chao, A. Sandhu and S. B. Jiang, "The diaphragm as an
537 anatomic surrogate for lung tumor motion," *Phys Med Biol* **54**, 3529-3541 (2009).

- 538 27. D. Ionascu, S. B. Jiang, S. Nishioka, H. Shirato and R. I. Berbeco, "Internal-external
539 correlation investigations of respiratory induced motion of lung tumors," *Med Phys*
540 **34**, 3893-3903 (2007).
- 541 28. E. Kanoulas, J. A. Aslam, G. C. Sharp, R. I. Berbeco, S. Nishioka, H. Shirato and S.
542 B. Jiang, "Derivation of the tumor position from external respiratory surrogates with
543 periodical updating of the internal/external correlation," *Phys Med Biol* **52**, 5443-5456
544 (2007).
- 545 29. H. Wu, G. Sandison, L. Zhao, Q. Zhao, H. Shirato and S. Jiang, "Correlation between
546 parameters describing tumour motion and its location in the lungs," *Australas Phys*
547 *Eng Sci Med* **30**, 341-344 (2007).
- 548 30. A. Kalet, G. Sandison, H. Wu and R. Schmitz, "A state-based probabilistic model for
549 tumor respiratory motion prediction," *Phys Med Biol* **55**, 7615-7631 (2010).
- 550 31. M. Isaksson, J. Jalden and M. J. Murphy, "On using an adaptive neural network to
551 predict lung tumor motion during respiration for radiotherapy applications," *Med Phys*
552 **32**, 3801-3809 (2005).
- 553 32. J. D. Hoisak, K. E. Sixel, R. Tirona, P. C. Cheung and J. P. Pignol, "Correlation of
554 lung tumor motion with external surrogate indicators of respiration," *Int J Radiat*
555 *Oncol Biol Phys* **60**, 1298-1306 (2004).
- 556 33. P. C. Chi, P. Balter, D. Luo, R. Mohan and T. Pan, "Relation of external surface to
557 internal tumor motion studied with cine CT," *Med Phys* **33**, 3116-3123 (2006).
- 558 34. R. Werner, J. Ehrhardt, R. Schmidt and H. Handels, "Patient-specific finite element
559 modeling of respiratory lung motion using 4D CT image data," *Med Phys* **36**, 1500-
560 1511 (2009).
- 561 35. P. L. Wilson and J. Meyer, "A spring-dashpot system for modelling lung tumour
562 motion in radiotherapy," *Computational and Mathematical Methods in Medicine* **11**,
563 13-26 (2010).

- 564 36. P. L. Wilson and J. Meyer, "A General Model of Lung Tumour Motion," in *Progress in*
565 *Industrial Mathematics at ECMI 2008, Vol. 15*, edited by A. D. Fitt, J. Norbury, H.
566 Ockendon and E. Wilson (Springer Berlin Heidelberg, 2010), pp. 1061-1066.
- 567 37. J. C. Lagarias, J. A. Reeds, M. H. Wright and P. E. Wright, "Convergence Properties
568 of the Nelder-Mead Simplex Method in Low Dimensions," *SIAM Journal of*
569 *Optimization* **9**, 112-147 (1998).
- 570 38. C. M. Jarque and A. K. Bera, "A Test for Normality of Observations and Regression
571 Residuals," *Int Stat Rev* **55**, 163-172 (1987).

572

573